Arcturus Therapeutics (ARCT) Tops Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.84), $0.21 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.96 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Helen of Troy rejects $37-per-share takeover bid from Spectrum Brands
- Marcus Corporation (MCS) Declares $0.09 Quarterly Dividend; 1.3% Yield
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
